Moleculin Biotech (MBRX) Issues Earnings Results, Misses Estimates By $0.05 EPS

Moleculin Biotech (NASDAQ:MBRX) posted its quarterly earnings data on Monday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05), Fidelity Earnings reports.

Shares of NASDAQ:MBRX traded up $0.01 on Wednesday, hitting $1.22. 796,968 shares of the company traded hands, compared to its average volume of 2,600,803. Moleculin Biotech has a 52 week low of $0.78 and a 52 week high of $3.15. The company has a market capitalization of $42.29 million, a PE ratio of -2.39 and a beta of 2.26.

A number of brokerages have issued reports on MBRX. Zacks Investment Research lowered shares of Moleculin Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 14th. Maxim Group restated a “buy” rating and issued a $3.00 price target on shares of Moleculin Biotech in a research report on Tuesday, February 5th. Finally, ValuEngine lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th.

ILLEGAL ACTIVITY WARNING: “Moleculin Biotech (MBRX) Issues Earnings Results, Misses Estimates By $0.05 EPS” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://transcriptdaily.com/2019/05/15/moleculin-biotech-mbrx-issues-earnings-results-misses-estimates-by-0-05-eps.html.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Read More: Market Capitalization and Individual Investors

Earnings History for Moleculin Biotech (NASDAQ:MBRX)

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.